Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Barclays analyst Gena Wang maintains PTC Therapeutics (NASDAQ:PTCT) with a Equal-Weight and raises the price target from $46...
Citigroup analyst Geoff Meacham maintains PTC Therapeutics (NASDAQ:PTCT) with a Neutral and raises the price target from $50...
TD Cowen analyst Joseph Thome maintains PTC Therapeutics (NASDAQ:PTCT) with a Hold and raises the price target from $50 to $63.
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Outperform and raises the price target fr...
Goldman Sachs analyst Paul Choi maintains PTC Therapeutics (NASDAQ:PTCT) with a Sell and raises the price target from $44 to...
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target ...
PTC Therapeutics (NASDAQ:PTCT) raises FY2025 sales outlook from $650.000 million-$800.000 million to $750.000 million-$800.000 ...
PTC Therapeutics (NASDAQ:PTCT) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $(1....
